Targovax granted EU Patent for mutant-RAS neoantigen platform 2nd generation product TG02
Provides IP protection of TG02 in Europe until 09.12.2033Oslo, 19 June 2018: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), is a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, announces that the European Patent Office has granted European Patent no 3079715, A Peptide mixture. The patent protects the composition of Targovax's mutant-RAS specific neoantigen vaccine TG02, for stimulating the immune system of cancer patients with RAS mutated tumors. Targovax’s proprietary mutant-RAS neoantigen vaccine platform